States Modify PSE Rx-Only Proposals To Curb Meth Production
This article was originally published in The Tan Sheet
Executive Summary
Legislators in Kentucky debate requiring a prescription for purchase of OTC pseudoephedrine over monthly and annual limits, while Oklahoma lawmakers consider requiring pharmacists to determine a patient’s need. CHPA opposes further limits on access and promotes electronic tracking with stop-sale technology.
You may also be interested in...
Research Refutes Rx-Only Pseudoephedrine Requirements
Research shows Rx requirements “do not effectively reduce methamphetamine’s overall impact on a given state,” CHPA President Scott Melville says. One study found Oregon’s Rx-only law has not dramatically reduced meth lab incidents compared to other states and the second showed the requirement would cost Oklahoma $59 million annually.
Georgia Limits OTC Pseudoephedrine Sales To Pharmacies
Georgia lawmakers approve a new tactic to prevent the diversion of OTC pseudoephedrine products to making methamphetamine – limiting sales to pharmacies.
Coalition Pushes Congress On OTC Purchases With Health Savings Accounts
The Health Choices Coalition sent letters urging House and Senate members to support legislation that would strike the health care reform law requirement that consumers obtain a prescription in order to purchase OTCs with a pre-tax savings account.